公开(公告)号：US10745306B2

公开(公告)日：2020-08-18

申请号：US16390007

申请日：2019-04-22

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Seong Pil Jeong ,  Jae Woo Choi ,  Kyungjin Cho ,  Hien Thi Nguyen ,  Youngjae Kim ,  Am Jang ,  Seunghak Lee ,  Seockheon Lee

IPC: C02F3/04 ,  E03B3/06 ,  C02F1/00 ,  C02F3/34 ,  E03B3/34

Abstract: Provided is an aquifer storage and recovery system, in which microbes extracted from an underground aquifer are involved in an assimilable organic carbon (AOC) removal mechanism and applied to an aerobic reactor, and a predetermined portion of assimilable organic carbon in raw water is removed through the aerobic reactor.

公开(公告)号：US11142472B2

公开(公告)日：2021-10-12

申请号：US16677679

申请日：2019-11-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Seong Pil Jeong ,  Kyungjin Cho ,  Jae Woo Choi ,  Seok Won Hong ,  Seunghak Lee ,  Eun-Ju Kim ,  Jae Shik Chung ,  Hien Thi Nguyen ,  Youngjae Kim

IPC: C02F1/52 ,  E03B3/34 ,  C02F101/32 ,  C02F1/00

Abstract: The present invention is an aquifer storage and recovery system using a natural coagulant, in which in purifying raw water through aquifer storage and recovery, assimilable organic carbon (AOC) included in the raw water is effectively removed using a natural coagulant produced in the aquifer storage and recovery process, thereby reducing the time required to purify raw water by aquifer storage and recovery.

公开(公告)号：US10435408B2

公开(公告)日：2019-10-08

申请号：US15738225

申请日：2017-11-06

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah Choo ,  Youngjae Kim ,  Jihye Seong ,  Ghil Soo Nam ,  Yong Seo Cho

IPC: C07D487/04 ,  C07D498/04 ,  A61K31/55 ,  A61K31/4162 ,  A61P25/22 ,  A61P25/24

Abstract: Azepine derivatives acting on 5-HT7 receptors and pharmaceutically acceptable salts thereof are disclosed. The azepine derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for and high antagonistic activities on 5-HT7 receptors. Due to these advantages, the azepine derivatives and the pharmaceutically acceptable salts thereof can be applied to therapeutic or prophylactic agents for central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, biorhythm dysregulation, sleep disturbance, and smooth muscle diseases where 5-HT7 receptors antagonistic activity is required.

公开(公告)号：US09260448B2

公开(公告)日：2016-02-16

申请号：US14038324

申请日：2013-09-26

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah Choo ,  Sun Joon Min ,  Seon Hee Seo ,  Jee Yeon Kim ,  Yoo Ran Ki ,  Min Joo Kim ,  Sora Kim ,  Youngjae Kim

IPC: A01N43/90 ,  A61K31/519 ,  C07D491/00 ,  C07D495/00 ,  C07D495/04

CPC classification number: C07D495/04 ,  A61K31/519

Abstract: Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

Abstract translation: 公开了作为代谢型谷氨酸受体亚型1的拮抗剂的噻吩并嘧啶酮衍生物。噻吩并嘧啶酮衍生物显示针对代谢型谷氨酸受体相关疾病的药理学活性，包括疼痛，如神经性疼痛和偏头痛，精神疾病如焦虑障碍和精神分裂症，尿 失禁和神经变性疾病，如帕金森病和阿尔茨海默病。 还公开了制备噻吩并嘧啶酮衍生物的方法和含有噻吩并嘧啶酮衍生物作为活性成分的药物组合物。

公开(公告)号：US09663464B2

公开(公告)日：2017-05-30

申请号：US14629821

申请日：2015-02-24

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah Choo ,  Gyo Chang Keum ,  Youngjae Kim ,  Mi Young Yeom

IPC: C07D403/06 ,  A61K31/496 ,  C07D209/86 ,  C07D401/06 ,  C07D413/06

CPC classification number: C07D209/86 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06

Abstract: The present invention provides a carbazole derivative represented by Formula 1: wherein X is CH2 or C(O), Y is selected from NR1R2, piperidinyl groups in which two of the carbon atoms are substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups, n is an integer from 2 to 5, R1 and R2, which may be identical or different, are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 may be bonded together to form a ring, R3 and R4, which may be identical or different, are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20140228565A1

公开(公告)日：2014-08-14

申请号：US14038324

申请日：2013-09-26

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah CHOO ,  Sun Joon Min ,  Seon Hee Seo ,  Jee Yeon Kim ,  Yoo Ran Ki ,  Min Joo Kim ,  Sora Kim ,  Youngjae Kim

IPC: C07D495/04

CPC classification number: C07D495/04 ,  A61K31/519

Abstract: Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

Abstract translation: 公开了作为代谢型谷氨酸受体亚型1的拮抗剂的噻吩并嘧啶酮衍生物。噻吩并嘧啶酮衍生物显示针对代谢型谷氨酸受体相关疾病的药理学活性，包括疼痛，如神经性疼痛和偏头痛，精神疾病如焦虑障碍和精神分裂症，尿 失禁和神经变性疾病，如帕金森病和阿尔茨海默病。 还公开了制备噻吩并嘧啶酮衍生物的方法和含有噻吩并嘧啶酮衍生物作为活性成分的药物组合物。